These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 100708)

  • 41. Glucocerebrosidase inhibitors: future drugs for the treatment of Gaucher disease?
    Trapero A; Llebaria A
    Future Med Chem; 2014 Jun; 6(9):975-8. PubMed ID: 25068980
    [No Abstract]   [Full Text] [Related]  

  • 42. Trials of verapamil and dantrolene sodium in McArdle disease.
    Lane RJ; Turnbull DM; Hudgson P; Walton J
    Muscle Nerve; 1984 Sep; 7(7):592-4. PubMed ID: 6399928
    [No Abstract]   [Full Text] [Related]  

  • 43. Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases.
    Cox TM
    Curr Opin Investig Drugs; 2010 Oct; 11(10):1169-81. PubMed ID: 20872320
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Alpha-glucosidase administration: experiences in two patients with glycogen storage disease compared with animal experiments.
    Huijing F; Waltuck BL; Whelan WJ
    Birth Defects Orig Artic Ser; 1973 Mar; 9(2):191-4. PubMed ID: 4611530
    [No Abstract]   [Full Text] [Related]  

  • 45. Enzyme replacement in Pompe disease with an alpha-glucosidase-low density lipoprotein complex.
    Williams JC; Murray AK
    Birth Defects Orig Artic Ser; 1980; 16(1):415-23. PubMed ID: 7004520
    [No Abstract]   [Full Text] [Related]  

  • 46. Gaucher disease.
    Butters TD
    Curr Opin Chem Biol; 2007 Aug; 11(4):412-8. PubMed ID: 17644022
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Experiences after long-term treatment of a type I Gaucher disease patient with liposome-entrapped glucocerebroside: beta-glucosidase.
    Gregoriadis G; Neerunjun D; Meade TW; Goolamali SK; Weereratne H; Bull G
    Birth Defects Orig Artic Ser; 1980; 16(1):383-92. PubMed ID: 6778529
    [No Abstract]   [Full Text] [Related]  

  • 48. [Method of action of zinc glucagon in treatment of glycogenosis].
    François R; Ruitton-Ugliengo A; Picaud JJ; Moreau P; Pinçon JA; Requien ; Poncet J
    Pediatrie; 1968 Sep; 23(6):623-9. PubMed ID: 5262974
    [No Abstract]   [Full Text] [Related]  

  • 49. Enzyme therapy: problems and solutions.
    Holcenberg JS
    Annu Rev Biochem; 1982; 51():795-812. PubMed ID: 6810751
    [No Abstract]   [Full Text] [Related]  

  • 50. Taliglucerase alfa in Gaucher disease: Description of a Brazilian experience.
    Cravo R; Rotman V; Oliveira PMN; Defendi HGT; Conceição DA; Xavier JR; Chertkoff R; Noronha TG; Maia MLS
    Blood Cells Mol Dis; 2018 Feb; 68():160-162. PubMed ID: 28131618
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease.
    Di Rocco M; Giona F; Carubbi F; Linari S; Minichilli F; Brady RO; Mariani G; Cappellini MD
    Haematologica; 2008 Aug; 93(8):1211-8. PubMed ID: 18603565
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lysosomal storage diseases: natural history and ethical and economic aspects.
    Beutler E
    Mol Genet Metab; 2006 Jul; 88(3):208-15. PubMed ID: 16515872
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Branching enzyme-deficiency glycogenosis: studies in therapy.
    Fernandes J; Huijing F
    Arch Dis Child; 1968 Jun; 43(229):347-52. PubMed ID: 5240133
    [No Abstract]   [Full Text] [Related]  

  • 54. Liposomes - methodology and applications.
    Ryman BE; Tyrrell DA
    Front Biol; 1979; 48():549-74. PubMed ID: 387469
    [No Abstract]   [Full Text] [Related]  

  • 55. Therapeutic strategies to ameliorate lysosomal storage disorders--a focus on Gaucher disease.
    Sawkar AR; D'Haeze W; Kelly JW
    Cell Mol Life Sci; 2006 May; 63(10):1179-92. PubMed ID: 16568247
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Comparative Study on the Alterations of Endocytic Pathways in Multiple Lysosomal Storage Disorders.
    Rappaport J; Manthe RL; Solomon M; Garnacho C; Muro S
    Mol Pharm; 2016 Feb; 13(2):357-368. PubMed ID: 26702793
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Gaucher disease type 1--therapeutic results of enzyme substitution].
    Steensberg J; Nielsen KG; Brandt NJ
    Ugeskr Laeger; 1998 Jun; 160(26):3929-30. PubMed ID: 9656836
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ten plus one challenges in diseases of the lysosomal system.
    Grabowski GA; Whitley C
    Mol Genet Metab; 2017; 120(1-2):38-46. PubMed ID: 27923545
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification and use of biomarkers in Gaucher disease and other lysosomal storage diseases.
    Aerts JM; Hollak CE; van Breemen M; Maas M; Groener JE; Boot RG
    Acta Paediatr Suppl; 2005 Mar; 94(447):43-6; discussion 37-8. PubMed ID: 15895711
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of lysosomes in the pathogeny of storage diseases.
    Hers HG
    Arch Belg Dermatol Syphiligr; 1972; 28(1):51-7. PubMed ID: 4266285
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.